Correction To: Surfactant Protein A As a Biomarker of Outcomes of Anti-fibrotic Drug Therapy in Patients with Idiopathic Pulmonary Fibrosis

Overview

Journal BMC Pulm Med

Publisher Biomed Central

Specialty Pulmonary Medicine

Date 2020 May 9

PMID 32380992

Citations 1

Authors

Takumi Yoshikawa

Mitsuo Otsuka

Hirofumi Chiba

Kimiyuki Ikeda

Yuki Mori

Yasuaki Umeda

Hirotaka Nishikiori

Koji Kuronuma

Hiroki Takahashi

Affiliations

Soon will be listed here.

Abstract

Following publication of the original article [1], the authors have flagged that there is an error in Fig. 3.

Citing Articles

Serum SP-A and KL-6 levels can predict the improvement and deterioration of patients with interstitial pneumonia with autoimmune features.

Wang J, Zheng P, Huang Z, Huang H, Xue M, Liao C BMC Pulm Med. 2020; 20(1):315.

PMID: 33267857 PMC: 7709263. DOI: 10.1186/s12890-020-01336-y.

References

Yoshikawa T, Otsuka M, Chiba H, Ikeda K, Mori Y, Umeda Y . Surfactant protein A as a biomarker of outcomes of anti-fibrotic drug therapy in patients with idiopathic pulmonary fibrosis. BMC Pulm Med. 2020; 20(1):27. PMC: 6995128. DOI: 10.1186/s12890-020-1060-y. View